When was argenx founded?

argenx was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is argenx located?

argenx is headquartered in Ghent, Belgium. It is registered at Boston, Massachusetts.

Who is the current CEO of argenx?

Tim Van Hauwermeiren of argenx.

How many employees does argenx have?

As of May 31, 2026, the latest employee count at argenx is 2227.

Is argenx a funded company?

argenx is a funded company, having raised a total of $61.9M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 09, 2009.

When was the latest funding round of argenx?

argenx's latest funding was a $***** Post IPO round on Mar 24, 2022, with participation from 0 investor.

What is the annual revenue of argenx?

Annual revenue of argenx is more than €1B as on Dec 31, 2024

Where does argenx rank among its competitors?

argenx ranks 5th amongst 674 active competitors, of which 208 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of argenx?

argenx's top competitors include Alexion, Biogen and Abcellera Biologics. Among them, Biogen secured the most recent funding round in February, 2024.

argenx - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.

Website: argenx.com
Email ID: *****@argenx.com
Phone Number: +32 **********
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2008

Location

Ghent, Belgium

Stage

Public

Total Funding

$61.9M in 11 rounds

Latest Funding Round

Post IPO, Mar 24, 2022, $*****

Investors

Omnes Capital & 21 more

Ranked

5^th among 674 active competitors

Annual Revenue

€1B+ as on Dec 31, 2024

Employee Count

2,227 as on May 31, 2026

Investment & Acquisitions

Unnatural Products & 1 more

Similar Companies

Alexion & 806 more

Exit Details

Public

View argenx's full profile

argenx is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
argenx CIN: 0818.292.196 , Belgium, Active	Sep 03, 2009	€1B+ (As on Dec 31, 2024)	355 (As on Dec 31, 2022)	-
ARGENX US INC CIN: 364880497 , United States, Active	Dec 31, 1999	-	705 (As on Dec 31, 2024)	-

argenx got listed on Jul 10, 2014.

Click here to take a look at argenx's IPO in detail

argenx has raised a total funding of $61.9M over 11 rounds. Its first funding round was on Sep 09, 2009. argenx has 22 institutional investors.

Here is the list of recent funding rounds of argenx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 24, 2022	4269417	Post IPO	6174934	2402450	6571638	7980186
May 2020	2985280	Post IPO	1378950	3114810	1666070	4850306
Nov 06, 2019	9548329	Post IPO	8288189	8334572	8198212	4893523

Access funding benchmarks and valuations. Sign up today!

View details of argenx's funding rounds and investors

The founders of argenx is Tim Van Hauwermeiren.

Here are the details of argenx's key team members:

Tim Van Hauwermeiren: Co-Founder & CEO of argenx.

View details of argenx's Founder profiles and Board Members

argenx's employee count trend

argenx has 2,227 employees as of May 26. Here is argenx's employee count trend over the years:

Uncover argenx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of argenx include Alexion, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of argenx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	HBM Healthcare Investments, Eiffel Investment Group ... & 20 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
7th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
9th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	Woodford Investment Management, General Atlantic ... & 50 others	69/100
10th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100